Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 10:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–8 of 8 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Non Small Cell Lung Cancer
Interventions
Gotistobart, Docetaxel
Drug
Lead sponsor
OncoC4, Inc.
Industry
Eligibility
18 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
46
States / cities
Dothan, Alabama • Russellville, Arkansas • Cerritos, California + 42 more
Conditions
Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
Interventions
ONC-392, Pembrolizumab
Drug
Lead sponsor
OncoC4, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
21
States / cities
Goodyear, Arizona • Phoenix, Arizona • Danbury, Connecticut + 18 more
Conditions
Advanced Solid Tumor
Interventions
ONC-783
Drug
Lead sponsor
OncoC4, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Conditions
Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Colorectal Cancer, Sarcomas, Metastatic Prostate Cancer, Ovarian Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer, Pancreas Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Urothelial Carcinoma
Interventions
ONC-392, Pembrolizumab, Docetaxel
Drug
Lead sponsor
OncoC4, Inc.
Industry
Eligibility
18 Years and older
Enrollment
733 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
33
States / cities
Springdale, Arkansas • Davis, California • Downey, California + 27 more
Enrolling by invitation Phase 3 Interventional

Gotistobart Long Term Extension (LTE) Study

NCT07659379
Conditions
Advanced Solid Tumor
Interventions
Gotistobart
Drug
Lead sponsor
OncoC4, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2037
U.S. locations
2
States / cities
Fort Worth, Texas • Tyler, Texas
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
ONC-392 low, ONC-392 high, lutetium Lu 177 vipivotide tetraxetan
Drug
Lead sponsor
OncoC4, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
23
States / cities
Sacramento, California • Aurora, Colorado • Tampa, Florida + 19 more
Conditions
Advanced Solid Tumor
Interventions
AI-081
Drug
Lead sponsor
OncoC4, Inc.
Industry
Eligibility
18 Years and older
Enrollment
387 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
21
States / cities
Birmingham, Alabama • Springdale, Arkansas • Washington D.C., District of Columbia + 18 more
Conditions
Advanced Solid Tumor
Interventions
ONC-841
Drug
Lead sponsor
OncoC4, Inc.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
8
States / cities
Sacramento, California • Gainesville, Florida • Kissimmee, Florida + 5 more